What is HC Wainwright's Estimate for PSTV Q1 Earnings?
HC Wainwright estimates Plus Therapeutics' Q1 2026 EPS at ($0.04), maintaining a "Buy" rating with a $2.00 target price. The consensus full-year EPS is ($2.30). Other analysts have varied ratings, with a consensus "Moderate Buy" and a $7.25 average price target. Plus Therapeutics' stock opened at $0.60, with a market cap of $82.22 million. Institutional investors have recently adjusted their positions in the company.
Plus Therapeutics, Inc. (NASDAQ:PSTV - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Plus Therapeutics in a research note issued on Wednesday, November 26th. HC Wainwright analyst S. Lee anticipates that the company will post earnings of ($0.04) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $2.00 target price on the stock. The consensus estimate for Plus Therapeutics' current full-year earnings is ($2.30) per share. HC Wainwright also issued estimates for Plus Therapeutics' Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.04) EPS and Q4 2026 earnings at ($0.04) EPS.
Plus Therapeutics (NASDAQ:PSTV - Get Free Report) last announced its earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). The company had revenue of $1.40 million during the quarter, compared to analysts' expectations of $1.50 million.
Get Plus Therapeutics alerts:
A number of other equities analysts have also issued reports on the stock. Maxim Group lowered their target price on shares of Plus Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research report on Monday, August 18th. Ascendiant Capital Markets lowered their price objective on shares of Plus Therapeutics from $21.00 to $19.00 and set a "buy" rating on the stock in a research report on Friday, November 21st. D Boral Capital upgraded shares of Plus Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 3rd. Wall Street Zen upgraded shares of Plus Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 16th. Finally, Zacks Research lowered Plus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $7.25.
Check Out Our Latest Analysis on Plus Therapeutics
Plus Therapeutics Trading Up 6.7%
Shares of NASDAQ PSTV opened at $0.60 on Thursday. The stock has a market cap of $82.22 million, a P/E ratio of -0.27 and a beta of 0.77. Plus Therapeutics has a twelve month low of $0.16 and a twelve month high of $2.31. The stock has a 50 day moving average of $0.59 and a two-hundred day moving average of $0.48.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in PSTV. Virtu Financial LLC purchased a new position in Plus Therapeutics during the first quarter worth about $38,000. Susquehanna International Group LLP acquired a new position in Plus Therapeutics during the 3rd quarter worth approximately $46,000. Jane Street Group LLC purchased a new position in shares of Plus Therapeutics during the 2nd quarter worth approximately $41,000. Scientech Research LLC acquired a new stake in shares of Plus Therapeutics in the 3rd quarter valued at approximately $100,000. Finally, Altium Capital Management LLC acquired a new stake in shares of Plus Therapeutics in the 3rd quarter valued at approximately $628,000. 3.28% of the stock is currently owned by institutional investors and hedge funds.
Plus Therapeutics Company Profile
(Get Free Report)Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Read More
- Five stocks we like better than Plus Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- Why Gold Loves Trump as Much as Trump Loves Gold
- What Do S&P 500 Stocks Tell Investors About the Market?
- Google's Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage
- What is the Euro STOXX 50 Index?
- Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Plus Therapeutics Right Now?
Before you consider Plus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Plus Therapeutics wasn't on the list.
While Plus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
